公开(公告)号：US12103951B2

公开(公告)日：2024-10-01

申请号：US17806834

申请日：2022-06-14

申请人： Christopher Joseph Soares

发明人： Christopher Joseph Soares

IPC分类号： C07K14/435 ,  A61K38/00 ,  A61P3/06 ,  C07K14/57 ,  C07K14/575

CPC分类号： C07K14/435 ,  A61P3/06 ,  C07K14/57527 ,  A61K38/00

摘要： Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.

公开(公告)号：US20240254254A1

公开(公告)日：2024-08-01

申请号：US18593028

申请日：2024-03-01

申请人： Crosslink Therapeutics Inc.

发明人： Rodolfo J. CHAPARRO ,  Ronald D. SEIDEL, III

IPC分类号： C07K16/30 ,  A61K38/00 ,  C07K14/525 ,  C07K14/54 ,  C07K14/55 ,  C07K14/57 ,  C07K14/705 ,  C07K16/28

CPC分类号： C07K16/30 ,  C07K14/525 ,  C07K14/5255 ,  C07K14/5418 ,  C07K14/5428 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/57 ,  C07K14/70521 ,  C07K14/70532 ,  C07K14/70575 ,  C07K16/2803 ,  C07K16/2806 ,  C07K16/2809 ,  C07K16/2812 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2896 ,  A61K38/00 ,  C07K2318/10 ,  C07K2319/30

摘要： The present disclosure provides polypeptide constructs that act as agonists of immune cell function when exposed to sufficient levels of ATP to cause their assembly into dimers or higher level complexes (e.g., trimers, tetramers, etc.). The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cell and/or NK cells) that function to promote anti-tumor immune responses. The constructs may be employed as anticancer agents/therapeutics for the treatment of solid tumors that have elevated levels of ATP.

公开(公告)号：US12016882B2

公开(公告)日：2024-06-25

申请号：US16760666

申请日：2018-11-20

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Khalid Shah

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K35/12 ,  A61K35/28 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30

CPC分类号： A61K35/17 ,  A61K35/28 ,  A61P35/00 ,  C07K14/5409 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K14/7051 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/30 ,  A61K9/0019 ,  A61K2035/128

摘要： This technology describes novel cell based combined therapeutic modalities that induces mechanism based tumor cell killing in a broad spectrum of sensitive and resistant tumors. These new agents are tumor specific and target a broad spectrum of solid tumors.

公开(公告)号：US20240043535A1

公开(公告)日：2024-02-08

申请号：US18067330

申请日：2022-12-16

申请人： Hoffmann-La Roche Inc.

发明人： Maria Amann ,  Alejandro Carpy Gutierrez Cirlos ,  Christina Claus ,  Laura Codarri Deak ,  Diana Darowski ,  Tanja Fauti ,  Claudia Ferrara Koller ,  Anne Freimoser-Grundschober ,  Sylvia Herter ,  Thomas Hofer ,  Christian Klein ,  Laura Lauener ,  Stephane Leclair ,  Ekkehard Moessner ,  Christiane Neumann ,  Pablo Umaña ,  Ali Bransi ,  Marlena Surówka

IPC分类号： C07K16/28 ,  C07K14/55 ,  C07K14/54 ,  C07K14/56 ,  C07K14/57 ,  A61P35/00

CPC分类号： C07K16/2809 ,  C07K16/2818 ,  C07K16/2878 ,  C07K14/55 ,  C07K14/5418 ,  C07K14/5443 ,  C07K14/56 ,  C07K14/57 ,  C07K14/54 ,  C07K16/283 ,  A61P35/00 ,  C07K2319/30

摘要： The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

公开(公告)号：US11820807B2

公开(公告)日：2023-11-21

申请号：US15177605

申请日：2016-06-09

申请人： UBI Pharma Inc ,  Chang-Yi Wang

发明人： Chang-Yi Wang ,  Wen-Jiun Peng ,  Wei-Ting Kao

IPC分类号： C07K14/705 ,  C07K14/745 ,  C07K19/00 ,  C07K14/565 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/57 ,  C12N9/64

CPC分类号： C07K14/745 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K19/00 ,  C07K2317/53 ,  C07K2319/03 ,  C12N9/644

摘要： A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.

公开(公告)号：US20230355804A1

公开(公告)日：2023-11-09

申请号：US18013409

申请日：2021-06-29

申请人： Flagship Pioneering Innovations V, Inc.

发明人： Darby Rye Schmidt ,  Niranjana Aditi Nagarajan ,  William Joseph Kaiser ,  Peter Joseph Gough ,  Sabin Dhakal

IPC分类号： A61K48/00 ,  C12N7/00 ,  A61K39/09 ,  A61K39/07 ,  A61K39/00 ,  A61K39/395 ,  A61K31/167 ,  A61K31/18 ,  A61K31/4045 ,  A61K31/165 ,  A61K31/4406 ,  A61K31/506 ,  A61P35/00 ,  C07K14/705 ,  C07K14/535 ,  C07K14/545 ,  C07K14/55 ,  C07K14/54 ,  C07K14/525 ,  C07K14/57 ,  C12N9/12

CPC分类号： A61K48/0041 ,  C12N7/00 ,  A61K39/092 ,  A61K39/07 ,  A61K39/4631 ,  A61K39/3955 ,  A61K31/167 ,  A61K31/18 ,  A61K31/4045 ,  A61K31/165 ,  A61K31/4406 ,  A61K31/506 ,  A61P35/00 ,  C07K14/70578 ,  C07K14/705 ,  C07K14/535 ,  C07K14/545 ,  C07K14/55 ,  C07K14/5406 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/525 ,  C07K14/57 ,  C12N9/12 ,  C12Y207/11001 ,  C12N2710/16622 ,  C12N2710/16671 ,  C12N2710/24122 ,  C12N2710/16632 ,  A61K2039/585

摘要： In certain aspects, the disclosure relates to a virus engineered to comprise one or more polynucleotides that promote thanotransmission by a target cell. Thanotransmission is communication between cells that is a result of activation of a cell turnover pathway in a target cell, which signals a responding cell to undergo a biological response. Methods of promoting thanotransmission by a target cell, methods of promoting an immune response in a subject, and methods of treating cancer in a subject are also disclosed.

公开(公告)号：US11713467B2

公开(公告)日：2023-08-01

申请号：US16062983

申请日：2016-12-16

申请人： OncoSec Medical Incorporated

发明人： Jean Campbell ,  David A. Canton ,  Robert H. Pierce

IPC分类号： C12N15/85 ,  C07K14/54 ,  C07K14/52 ,  C07K14/715 ,  A61K9/00 ,  A61P35/00 ,  C07K14/57 ,  G01N33/574

CPC分类号： C12N15/85 ,  A61K9/0009 ,  A61K9/0019 ,  A61P35/00 ,  C07K14/52 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/57 ,  C07K14/7155 ,  G01N33/574 ,  C07K2319/00

摘要： Provided are plasmid vector constructs encoding multiple immunomodulatory proteins where each protein or component thereof can be expressed utilizing appropriate promotors and/or translation modifiers. Additional immunomodulatory proteins and genetic adjuvants containing shared tumor antigens can be added to further therapeutic potential as well as allow tracking of therapeutic treatment. Also provides are methods of expressing the plasmid constructs.

公开(公告)号：US20230227554A1

公开(公告)日：2023-07-20

申请号：US17998092

申请日：2020-10-22

申请人： ZHEJIANG UNIVERSITY

发明人： Jin ZHANG ,  Lin TIAN ,  Anhua LEI

IPC分类号： C07K16/28 ,  C07K14/57 ,  C12N5/0786

CPC分类号： C07K16/2809 ,  C07K14/57 ,  C07K16/2815 ,  C07K16/2818 ,  C12N5/0645 ,  C07K2317/622

摘要： Provided are a chimeric antigen receptor, a macrophage expressing same, a method for adjusting macrophage polarization, and the use thereof. The intracellular domain of the chimeric antigen receptor contains an IFN-γ receptor, and the macrophage expressing the chimeric antigen receptor can maintain an M1 type status for a relatively long time, thereby enhancing the activity of the macrophage M1 type after tumor cell antigens are combined with the chimeric antigen receptor.

公开(公告)号：US20230035290A1

公开(公告)日：2023-02-02

申请号：US17699846

申请日：2022-03-21

申请人： CytomX Therapeutics, Inc.

发明人： Nancy E. Stagliano ,  James W. West ,  Kathryn Kamath ,  Paul H. Bessette ,  Jason G. Sagert

IPC分类号： C07K14/56 ,  C07K14/00 ,  C07K14/555 ,  A61K47/64 ,  A61K47/65 ,  C07K19/00 ,  C07K14/565 ,  C07K14/57 ,  C07K16/00 ,  G01N33/68 ,  C07K14/705 ,  C12N15/10

摘要： The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.

公开(公告)号：US11326170B2

公开(公告)日：2022-05-10

申请号：US16484090

申请日：2018-04-17

申请人： CHANGCHUN HUAPU BIOTECHNOLOGY CO., LTD.

发明人： Tao Huang ,  Yan Shao ,  Jun Zhang

IPC分类号： C07H21/02 ,  A61K48/00 ,  C12N15/117 ,  A61P35/00 ,  C07K14/57 ,  C12N15/11 ,  A61K45/06 ,  A61K31/7115

摘要： Provided are immunomodulatory polynucleotides with sequences of SEQ ID NOs:1-12 which are TLR9 agonists. Therapeutic combinations comprising the immunomodulatory polynucleotides are provided too.